Abstract: The invention relates to the use of compounds of formula (I): wherein X is —C(O)—, —C(S)—, —C?NOH, or —CH(R7)— wherein R7 is hydrogen, hydroxy, C1-7alkoxy, —OR8 or —NR8R9 (wherein R8 is a group —Y1R10 (wherein Y1 is a direct bond, —C(O)—, —C(S)—, —S—, —C(O)O, —C(O)NR11—, —SO2— or —SO2NR12— (wherein R11 and R12, which may be the same or different, each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and R10 is as defined herein, and R9 includes hydrogen; R1, R2 and R3 are as defined herein and are preferably methyl; R4, R5 and R6 are as defined herein with the proviso that R5 is not hydroxy, alkoxy, substituted alkoxy, —OPO3H2, —O—C1-7alkanoyl or benzyloxy; and salts thereof in the manufacture of a medicament for use in the production of a vascular damaging effect in warm-blooded animals such as humans.

Abstract: A range is disclosed of pyrimidine derivatives (I) which can act as inhibitors of cyclin dependent kinases (CDK's) and which thereby can provide useful therapeutic compounds for use in treatment of tumours or other cell proliferation disorders. The compounds of this invention bind to CDK molecules in a manner that appears to differ from that of known CDK inhibitors such as olomoucine and roscovitine.

Abstract: The invention concerns anti-tumor agents of formula (I), wherein each of R1, R2 and R3 has the meanings defined in the specification including hydrogen, (1-4C)alkyl, (3-4C)alkynyl and (1-4C)alkoxyl; each of R4 and R5 is (1-4C) alkyl; each of R6 and R7 is hydrogen or (1-4C)alkyl; X is N-(1-4C)alkylimino, N-(3-4C)alkenylimino, or (3-4C)alkynylimino; m is 1 or 2 and each R8 is as defined in the specification; each Y′ and Y2 is halogen, (1-4C)alkanesulphonyloxy, benzensulphonyloxy or phenyl-(1-4C)alkanesulfonyloxy; or a pharmaceutical acceptable salt thereof; provided that at least one of R1, R2 and R3 is other than hydrogen; a process for their preparation, pharmaceutical composition containing them and their use for producing an anti-proliferative effect in a warm-blooded animal.

Abstract: The invention concerns anti-tumour agents of formula (I) wherein each of R1, R2 and R3 has the meanings defined in the specification including hydrogen, (1-4C)alkyl, (3-4)alkenyl, (3-4C)alkynyl, amino, (1-4C)alkylamino and (1-4C)alkoxy; each of R4 and R5 is (1-4C)alkyl; each of R6 and R7 is hydrogen or (1-4C)alkyl; X is oxygen; m is 1 or 2 and each R8 is as defined in the specification; each of Y1 and Y2 is halogeno, (1-4C)alkanesulphonyloxy, benzenesulphonyloxy or phenyl-(1-4C)akanesulphonyloxy; or a pharmaceutically-acceptable salt thereof; provided that at least one of R1, R2 and R3 is other than hydrogen; a process for preparation, pharmaceutical compositions containing them and their use in the production of an anti-proliferative effect.

Abstract: Method of treating a tumour or other cell proliferation disorder which comprises administering an effective amount of a purine compound which inhibits cyclic dependent kinase activity. Novel purine compounds and pharmaceutical compositions are also disclosed.

Abstract: The invention relates to quinazoline derivatives, or pharmaceutically-acceptable salts thereof, which possess anti-tumour activity; to processes for their manufacture; and to pharmaceutical compositions containing them.The invention provides a quinazoline of the formula: ##STR1## wherein R.sup.1 includes hydrogen, amino and alkyl or alkoxy each of up to 4 carbon atoms;R.sup.2 includes hydrogen, alkyl, hydroxyalkyl and halogenoalkyl each of up to 4 carbon atoms;R.sup.3 is hydrogen or alkyl or up to 3 carbon atoms;Ar is phenylene or heterocyclene;L is a group of the formula --CO.NH--, --NH.CO--, --CO.NR.sup.4 --, --NR.sup.4.CO--, --CH.dbd.CH-- or --CO.O--, wherein R.sup.4 is alkyl of up to 4 carbon atoms; and Y is a branched alkyl group bearing substituents Y.sup.2 and Y.sup.3 the definition of each independently including hydroxy, cyano, aryl and heteroaryl, and the definition of Y.sup.

Abstract: The use of an olefinic compound of the formulaR.sup.1 R.sup.2 R.sup.3 C--CR.sup.4 =CR.sup.5 R.sup.6 (I),wherein R.sup.1 is a heterocyclyl radical selected from 1,2,4 -triazolyl, imidazolyl, 5-(1-6C alkyl)imidazol-1-yl, pyridyl and pyrimidinyl; R.sup.2 and R.sup.3, which may be the same or different, are each a hydrogen atom or a 1-6C alkyl radical; R.sup.4 is a phenyl or pyridyl radical, optionally bearing one or more substitutents selected from halogen atoms, amino, cyano, carbamoyl and nitro radicals, 1-6C alkyl, halogenoalkyl, alkoxy, halogenoalkoxy, alkylamino and alkylcarbamoyl radicals, di(1-6C alkyl)amino, di(1-6C alkyl)carbamoyl and 2-6C alkoxycarbonyl radicals; R.sup.5 is a hydrogen or halogen atom, a 1-6C alkyl radical or a phenyl radical optionally bearing one or more substituents as defined above for R.sup.4 ; and R.sup.6 is a phenyl or pyridyl radical optionally bearing one or more substitutents as defined above for R.sup.

Abstract: Diphenylethane derivatives of the formula ##STR1## are described; wherein R.sup.1 is a heterocyclyl radical selected from the group consisting of 1,2,4-triazolyl, optionally-substituted imidazolyl, pyridyl and pyrimidinyl radicals; R.sup.2 and R.sup.3, which may be the same or different, are each a hydrogen atom or a 1-6C alkyl radical; R.sup.4 and R.sup.5, which may be the same or different, are each a hydrogen or fluorine atom or a 1-6C alkyl radical; and A is a phenyl radical, optionally bearing one or more substituents selected from halogen atoms, cyano radicals or 1-4C halogenoalkyl or halogenoalkoxy radicals. Processes for their preparation are described, as is their use as aromatase inhibitors, for example in the treatment of cancer or as plant antifungal compounds.

Abstract: Azole derivatives of the formulasR.sup.1 --CR.sup.2 R.sup.3 --CHR.sup.4 --CR.sup.5 R.sup.6 --R.sup.7are described;wherein R.sup.1 is a heterocyclyl radicla selected from 1,2,4-triazolyl, optionally-substituted imidazolyl, pyridyl and pyrimidinyl radicals; R.sup.2 and R.sup.3, which may be the same or different, are each a hydrogen atom or a 1-6C alkyl radical; R.sup.5 and R.sup.6, which may be the same or different, are each a hydrogen or fluorine atom or a 1-6C alkyl radical; one of R.sup.4 and R.sup.7 is a 2-pyridyl or 2-thienyl radical, optionally bearing one or more substituents selected from halogen atoms, cyano radicals and 1-4C halogenoalkyl and halogenoalkoxy radicals, and the other of R.sup.4 and R.sup.7 is a 4-cyanophenyl radical or a 2-pyridyl or 2-thienyl radical optionally substituted as defined above. Processes for their preparation are described, as is their use as aromatase inhibitors, for example in the treatment of cancer, as plant antifungal agents or as plant growth regulatory agents.

Abstract: A 2-propanol derivative of the formula I, wherein R.sup.1 and R.sup.5, which may be the same or different, are each a triazolyl, imidazolyl, pyridyl or pyrimidinyl radical; R.sup.2, R.sup.3 and R.sup.4, which may be the same or different, are each a hydrogen atom, a 1-6C alkyl, halogenoalkyl or alkoxy radical, a 3-8C cycloalkyl radical, or a phenyl, naphthyl, phenoxy, naphthyloxy or phenyl (1-6C alkyl) radical, in each of which the aryl group optionally bears one or more substituents selected from halogen atoms, amino, carboxamido, cyano and nitro radicals, 1-6C alkyl, halogenoalkyl, alkoxy, halogenoalkoxy and alkylamino radicals, 3-8C cycloalkyl radicals, di(1-6C alkyl)amino radicals and 2-6C alkoxycarbonyl radicals; R.sup.6 is a phenyl or naphthyl radical optionally bearing one or more substituents as defined above; X is a direct bond, an alkylene, alkenylene or alkynylene radical, or an oxyalkylene or thioalkylene radical wherein respectively the oxygen or sulphur atom is bonded to R.sup.

Abstract: Heterocyclic compounds of the formula: ##STR1## wherein X and Y, which may be the same or different, are each a .dbd.N-- or .dbd.CH-- group and R is a phenyl radical which optionally bears one or more substituents selected from halogen atoms, amino, cyano, carbamoyl, hydroxy and nitro radicals, 1-6C alkyl, halogenoalkyl, alkoxy, halogenoalkoxy and alkylamino radicals, di(1-6C alkyl)amino and 2-6C alkoxycarbonyl radicals, and n is 1 to 6, but excluding the compound wherein X and Y are each .dbd.N--, R is 2,4-dichlorophenyl and n is 1; and the pharmaceutically or veterinarily acceptable acid addition salts thereof; processes for their manufacture; and pharmaceutical and veterinary compositions containing them.

Abstract: 1,3-Diazolyl-2-propanol derivatives of the formula ##STR1## wherein X and Y are N or CH, R.sup.1 is phenyl, heterocyclyl, heterocyclyl-alkyl, -alkenyl or -alkynyl, optionally substituted, R.sup.2 and R.sup.3 are hydrogen or alkyl, and R.sup.4 and R.sup.5 are hydrogen, amino, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, or alkenyl, or phenyl, phenylalkyl or phenylalkenyl, heterocycyl, heterocyclyalkyl or heterocyclylalkenyl, each optionally substituted, provided that when R.sup.1 is optionally substituted phenyl at least one of R.sup.1, R.sup.4 and R5 is, or contains, a phenyl ring bearing at least one substitutent selected from cyano, cyanoalkyl, nitro, aminocarbonylalkyl, halogeneoalkoxy and radicals of the formulae --CONR.sup.6 R.sup.7, --NHCOR.sup.8 or OR.sup.

Abstract: A heterocyclic compound of the formula I, as shown hereafter in these claims in which n is 0 or 1; A is a 1-4C alkylene radical which may optionally bear one or more 1-4C alkyl substituents; R.sup.1 and R.sup.2, which may be the same or different, are each a hydrogen or halogen atom, an amino, carbamoyl, cyano, hydroxy, nitro or sulphamoyl radical, a 1-6C alkyl, halogenoalkyl, alkoxy, halogenoalkoxy, alkylamino, alkylcarbamoyl or alkylsulphamoyl radical, a di(1-6C alkyl)-amino, di(1-6C alkyl)carbamoyl or di(1-6C alkyl)sulphamoyl radical, or a 2-7C alkoxycarbonyl radical; m is an integer of 1 to 5, R.sup.3 is a hydrogen or halogen atom or a 1-6C alkyl or halogenoalkyl radical; and R.sup.

Abstract: The use of an olefinic compound of the formulaR.sup.1 R.sup.2 R.sup.3 C-CR.sup.4 =CR.sup.5 R.sup.6 (I)wherein R.sup.1 is a heterocyclyl radical selected from 1,2,4-triazolyl, imidazolyl, 5-(1-6C alkyl)imidazol-1-yl, pyridyl and pyrimidinyl; R.sup.2 and R.sup.3, which may be the same or different, are each a hydrogen atom or a 1-6C alkyl radical; R.sup.4 is a phenyl or pyridyl radical, optionally bearing one or more substitutents selected from halogen atoms, amino, cyano, carbamoyl and nitro radicals, 1-6C alkyl, halogenoalkyl, alkoxy, halogenoalkoxy, alkylamino and alkylcarbamoyl radicals, di(1-6C alkyl)amino, di(1-6C alkyl)carbamoyl and 2-6C alkoxycarbonyl radicals; R.sup.5 is a hydrogen or halogen atom, a 1-6C alkyl radical or a phenyl radical optionally bearing one or more substituents as defined above for R.sup.4 ; and R.sup.6 is a phenyl or pyridyl radical optionally bearing one or more substituents as defined above for R.sup.

Abstract: This invention relates to novel antifungal azole compound of the formula: ##STR1## wherein X and Y are CH or N, R.sup.1 is optionally substituted phenyl or phenylalkyl, 1-6C alkyl or 3-8C cycloalkyl, R.sup.2 and R.sup.3 are hydrogen or 1-6C alkyl, and R.sup.4 and R.sup.5 are hydrogen, NH.sub.2, 1-6C alkyl, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylamino or alkenyl wherein each alkyl, alkoxy or alkenyl part is of 1-6C, phenyl, phenyl-(1-6C)-alkyl, phenoxy-(1-6C)-alkyl or phenyl-(2-6C)-alkenyl in which the phenyl may be optionally substituted, or a heterocyclyl, (heterocyclyl)-(1-6C)-alkyl or (heterocyclyl)-(2-6C)-alkenyl in each of which the heterocyclyl ring may be optionally substituted, provided at least one of R.sup.2, R.sup.3, R.sup.4 and R.sup.5 is other than hydrogen, and the acid addition salts of those compounds which contain a basic nitrogen; together with processes for their manufacture; compositions containing them; and a method of combatting plant fungal diseases.

Abstract: The invention relates to novel heterocyclic trichloromethyl derivatives, particularly 2-trichloromethyl-substituted quinazoline, benzo[d]-[1,3]-oxazine and benzo[e]-[1,3]-oxazine derivatives, for example 1,2-dihydro-2-trichloromethylquinazolin-4-one. The compounds of the invention are at least as effective as prior art trichloromethyl derivatives, which reduce the production of methane during the rumen metabolism of ruminant animals, and increase the formation of propionate at the expense of acetate, and hence improve the animals' rate of growth and their efficiency of food utilization.

Abstract: The disclosure relates to a method in the practice of animal husbandry which comprises the oral administration to ruminant animals of a benzo[1,3]dioxin derivative. The disclosure also relates to compositions containing such benzo[1,3]dioxin derivatives either in a form suitable for direct feeding to animals, or in the form of a concentrated premix; and to certain of the benzo[1,3]dioxin derivatives used in the method of the invention which are novel compounds.